Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking - 2003 -- Ignore unavailable to you. Want to Upgrade?

To: EVENT HORIZON III who wrote (116)	1/12/2003 2:19:39 PM
From: Icebrg	Respond to of 383

>>Curious any biotechs come to mind that are advancing any autism products through R&D or Phase testing?>> One such company is Cortex. It's a microbio. Market cap. is only 12 mUSD. (It's on Dr Tracy's B-list, though). And this is not completely off-topic here, as I have got some in my portfolio. Erik IRVINE, Calif. (April 30, 2002) — Cortex Pharmaceuticals, Inc. (AMEX: COR), today announced that the company is collaborating with several research organizations to carry out a phase II clinical study to evaluate one of the company’s AMPAKINE® compounds as a potential treatment for fragile X syndrome and autism. Organizations participating in the study include the FRAXA Research Foundation, Rush-Presbyterian-St. Luke’s Medical Center in Chicago, and the Child and Adolescent Psychiatry Department at the University of Chicago.... cortexpharm.com

To: EVENT HORIZON III who wrote (116)	1/12/2003 3:32:32 PM
From: scaram(o)uche	Respond to of 383

You'll want to look at Repligen (RGEN), for both a diagnostic and therapeutic angle. I'm not enthusiastic about their chances, but this could reflect ignorance. Not "off topic", as the RGEN ticker is similar to that of a popular contest pick, REGN........... The principals at RGEN are sincerely trying to attack "autism" and to turn around one of biotech's early flameouts. The company was flown into the ground by an earlier management team. They have sort of a pay-as-you-go business plan, based on the sale of protein A. There is also nice leverage, based on an immunosuppressant, CTLA4Ig. Used to be a great trading stock.

To: EVENT HORIZON III who wrote (116)	1/12/2003 3:40:31 PM
From: scott_jiminez	Respond to of 383

<<Curious any biotechs come to mind that are advancing any autism products through R&D or Phase testing? Diagnostics in advance of expression?>> Some questions: 1. Could you (or anyone else) provide a concise definition of Autism? Or is Autism a constellation of sociopathological behaviors (perhaps reflecting different biological/environmental roots) that have come to be grouped under a single rubric? 2. Your question about products appears to assume either some correlative factors have appeared with enough consistency or there is data on specific underlying organic anomalies to invite active pharmaceutical interest. Are there solid data to support these premises? These are not rhetorical questions. I just don't know.